<span item_type="fundamental" item_id="c5bc1c9fe503cba717a4e0b1a0da65c9" counter_id="ST/US/SRTAW" env="prod"></span><span item_type="announcement" item_id="581211382832043905" env="prod"></span><p>Revenue: As of FY2025 Q3, the actual value is USD 49.3 M.</p><p>EPS: As of FY2025 Q3, the actual value is USD -0.12.</p><p>EBIT: As of FY2025 Q3, the actual value is USD -6.749 M.</p><p></p><h3>Financial Metrics by Segment</h3><h4>Segment Revenue</h4><ul><li>Total revenue for Q3 2025 was $49.3 million, a 36.7% increase from $36.1 million in Q3 2024. Excluding the Keystone acquisition, revenue increased by 29.0%.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1779128/000162828025050785/srta-earningreleasexq32025.htm"></span></li></ul><h4>Operational Metrics</h4><ul><li>Net loss from continuing operations increased to - $9.7 million in Q3 2025 from - $5.6 million in Q3 2024, primarily due to a $5.2 million increase in realized loss from sales of short-term investments and a legal reserve.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1779128/000162828025050785/srta-earningreleasexq32025.htm"></span></li><li>Gross profit for Q3 2025 was $9.5 million, up 75.9% from $5.4 million in Q3 2024. The gross margin improved to 19.4% from 15.0% in the prior year period.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1779128/000162828025050785/srta-earningreleasexq32025.htm"></span></li><li>Adjusted EBITDA increased to $4.2 million in Q3 2025 from $0.1 million in Q3 2024, marking a significant improvement.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1779128/000162828025050785/srta-earningreleasexq32025.htm"></span></li><li>Medical Segment Adjusted EBITDA rose by 93.5% to $7.6 million in Q3 2025, with the margin increasing to 15.3% from 10.8% in Q3 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1779128/000162828025050785/srta-earningreleasexq32025.htm"></span></li></ul><h4>Cash Flow</h4><ul><li>Operating cash flow was - $37.3 million in Q3 2025, impacted by $44.3 million of Keystone acquisition consideration included in operating cash flow.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1779128/000162828025050785/srta-earningreleasexq32025.htm"></span></li><li>Free cash flow from continuing operations was $1.9 million in Q3 2025, excluding acquisition consideration and transaction costs.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1779128/000162828025050785/srta-earningreleasexq32025.htm"></span></li></ul><h4>Unique Metrics</h4><ul><li>No unique company-specific financial indicators were mentioned in the reference.<span class="superscript" item_id="0" item_type="announcement_file" value="2" url="https://www.sec.gov/Archives/edgar/data/1779128/000162828025050785/srta-20251110.htm"></span></li></ul><h4>Outlook / Guidance</h4><ul><li>Strata Critical Medical raised its 2025 revenue guidance to $185-195 million and reaffirmed its Adjusted EBITDA guidance of $13-14 million.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1779128/000162828025050785/srta-earningreleasexq32025.htm"></span></li></ul>

STRATA CRITICAL MED INC C/WTS 07/05/2026 (TO PUR COM) | 8-K: FY2025 Q3 Revenue: USD 49.3 M